Ligand id: 9805

Name: PRX-003

Compound class Antibody
imaprelimab (proposed INN) | PRX003
PRX-003 is an anti-MCAM mAb developed as a novel therapy for psoriasis. In patients with autoimmune diseases, a subset of MCAM+ve T cells (which have an effector memory T-helper 17 phenotype) produce high levels of pro-inflammatory IL-17 [1,3]. Pharmacological disruption of MCAM function is thought to be a valid mechanism for the treatment of autoimmune inflammation. Peptide sequence alignments identify PRX-003 as one of the preferred antibodies claimed in patent WO2014039975 [2] (SEQ IDs 119 and 123 match the sequences submitted to the WHO for INN imaprelimab). These peptide sequences map to the construct identified as h2120VH5/L3.
Database Links
Specialist databases
IMGT/mAb-DB 808
Other databases
GtoPdb PubChem SID 354702277